A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation
Background The grading of recommendation, assessment, development and evaluation
(GRADE) approach is widely implemented in health technology assessment and guideline …
(GRADE) approach is widely implemented in health technology assessment and guideline …
A systematic review on sex differences in adverse drug reactions related to psychotropic, cardiovascular, and analgesic medications
Background and objective: Adverse drug reactions (ADRs) are the main safety concerns of
clinically used medications. Accumulating evidence has shown that ADRs can affect men …
clinically used medications. Accumulating evidence has shown that ADRs can affect men …
晚期非小细胞肺癌维持治疗进展
李艳， 郭其森 - 中华肿瘤防治杂志, 2014 - cqvip.com
目的: 回顾非小细胞肺癌维持治疗的研究现状, 探讨维持治疗在晚期肺癌治疗中的临床意义及
如何选择最佳维持治疗方案. 方法: 应用PubMed 和CNKI 期刊全文数据库检索系统, 检索2003 …
如何选择最佳维持治疗方案. 方法: 应用PubMed 和CNKI 期刊全文数据库检索系统, 检索2003 …
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials
M Burotto, EE Manasanch, J Wilkerson, T Fojo - The oncologist, 2015 - academic.oup.com
Abstract Background. Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …
[HTML][HTML] Increasing the α 2, 6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer
JJ Park, M Lee - Gut and liver, 2013 - ncbi.nlm.nih.gov
Abnormal glycosylation due to dysregulated glycosyltransferases and glycosidases is a key
phenomenon of many malignancies, including colorectal cancer (CRC). In particular …
phenomenon of many malignancies, including colorectal cancer (CRC). In particular …
Upregulation and clinicopathological significance of long non-coding NEAT1 RNA in NSCLC tissues
LJ Pan, TF Zhong, RX Tang, P Li… - Asian Pacific journal …, 2015 - koreascience.kr
Background: Recent reports have shown that nuclear enriched abundant transcript 1
(NEAT1), a long noncoding RNA (lncRNA), contributes to the precise control of gene …
(NEAT1), a long noncoding RNA (lncRNA), contributes to the precise control of gene …
NQO1 protein expression predicts poor prognosis of non-small cell lung cancers
Z Li, Y Zhang, T Jin, J Men, Z Lin, P Qi, Y Piao, G Yan - BMC cancer, 2015 - Springer
Background High-level expression of NAD (P) H: quinoneoxidoreductase 1 (NQO1) has
been correlated with many types of human cancers, suggesting that NQO1 plays important …
been correlated with many types of human cancers, suggesting that NQO1 plays important …
[HTML][HTML] Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
V Vaccaro, I Sperduti, S Vari, E Bria… - World journal of …, 2015 - ncbi.nlm.nih.gov
Due to extremely poor prognosis, pancreatic cancer (PDAC) represents the fourth leading
cause of cancer-related death in Western countries. For more than a decade, gemcitabine …
cause of cancer-related death in Western countries. For more than a decade, gemcitabine …
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
G Bronte, C Rolfo, E Giovannetti, G Cicero… - Critical reviews in …, 2014 - Elsevier
Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line
JH Li, N Luo, MZ Zhong, ZQ Xiao, JX Wang, XY Yao… - Tumor Biology, 2016 - Springer
We aimed to explore the possible mechanism of microRNA-196a (miR-196a) inhibition and
reversion of drug resistance to cisplatin (DDP) of the A549/DDP non-small-cell lung cancer …
reversion of drug resistance to cisplatin (DDP) of the A549/DDP non-small-cell lung cancer …